Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAXBiotechnology
+$0.00 today
- Market cap
- $622.71M
- Beta
- -0.53
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$2.59
Volume 1.30M
Average 0.54M
BCAX Total Non-current Liabilities
All obligations due after more than one year.
Bicara Therapeutics Inc. Common StockNASDAQ: BCAX
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities remains negative
Q1 FY2026 total non-current liabilities was $301K, compared with $0 a year earlier. Over 3 fiscal years it compounded at +91.1% a year.
Context
- Total non-current liabilities amounted to 0.1% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Total non-current liabilities increased in 2 of the last 3 fiscal years.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 593K USD
- Year-over-year change
- -99.0%
- 3-year CAGR
- +91.1%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 593K | -99.0% |
| FY2024 | 2024-12-31 | 59.33M | +15151.9% |
| FY2023 | 2023-12-31 | 389K | +357.6% |
| FY2022 | 2022-12-31 | 85K | — |
Total Non-current Liabilities vs competitors
How BCAX compares with its peers on the latest reported figures
- BCAX's Mar 2026 total non-current liabilities of $301K is the 5th highest of the 6 companies compared; the peer median is $1.66M.
- Total non-current liabilities amounts to 0.1% of total assets for BCAX, versus a peer median of 0.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $100.74M | +11.9% | +16.9% | 46.2% | |
| Mar 2026 | $8.42M | +34.2% | +68.7% | 4.1% | |
| Mar 2026 | $1.66M | +236.3% | -19.1% | 0.4% | |
| Mar 2026 | $1.09M | — | — | 0.5% | |
BCAXBicara Therapeutics Inc. Common Stock | Mar 2026 | $301K | — | +91.1% | 0.1% |
| Mar 2026 | $122.37K | +48.1% | — | 0.2% | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding BCAX) | $1.66M | +41.2% | +16.9% | 0.5% | |
Competitors are the stored peer set for BCAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
Intrinsic Alpha fair value
Locked
Current Price
$9.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.